New G-CSF agonists for neutropenia therapy

Bibliography

• Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-53
   PubMed Web of Science ®Google Scholar
• Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:1526-30
   PubMed Web of Science ®Google Scholar
• Platzer E, Oez S, Welte K, et al. Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology 1986;172:185-93
   PubMed Web of Science ®Google Scholar
• Nagata S, Tsuchiya M, Asano S, et al. The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J 1986;5:575-81
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232:61-5
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994;84:1737-46
   PubMed Web of Science ®Google Scholar
• Inazawa J, Fukunaga R, Seto Y, et al. Assignment of the human granulocyte colony-stimulating factor receptor gene (CSF3R) to chromosome 1 at region p35-p34.3. Genomics 1991;10:1075-8
   PubMed Web of Science ®Google Scholar
• Germeshausen M, Skokowa J, Ballmaier M, et al. G-CSF receptor mutations in patients with congenital neutropenia. Curr Opin Hematol 2008;15:332-7
   PubMed Web of Science ®Google Scholar
• Nicholson SE, Novak U, Ziegler SF, Layton JE. Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 1995;86:3698-704
   PubMed Web of Science ®Google Scholar
• Tweardy DJ, Wright TM, Ziegler SF, et al. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 1995;86:4409-16
   PubMed Web of Science ®Google Scholar
• Rauprich P, Kasper B, Tidow N, Welte K. The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Blood 1995;86:4500-5
   PubMed Web of Science ®Google Scholar
• Bashey A, Healy L, Marshall CJ. Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway. Blood 1994;83:949-57
   PubMed Web of Science ®Google Scholar
• Sullivan R, Griffin JD, Simons ER, et al. Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol 1987;139:3422-30
   PubMed Web of Science ®Google Scholar
• Matsuda S, Shirafuji N, Asano S. Human granulocyte colony-stimulating factor specifically binds to murine myeloblastic NFS-60 cells and activates their guanosine triphosphate binding proteins/adenylate cyclase system. Blood 1989;74:2343-8
   PubMed Web of Science ®Google Scholar
• Duhrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81
   PubMed Web of Science ®Google Scholar
• Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-8
   PubMed Web of Science ®Google Scholar
• Colgan SP, Gasper PW, Thrall MA, et al. Neutrophil function in normal and Chediak-Higashi syndrome cats following administration of recombinant canine granulocyte colony-stimulating factor. Exp Hematol 1992;20:1229-34
   PubMed Web of Science ®Google Scholar
• Kitagawa S, Yuo A, Souza LM, et al. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide. Biochem Biophys Res Commun 1987;144:1143-6
   PubMed Web of Science ®Google Scholar
• Weisbart RH, Golde DW. Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 1989;3:401-9
   PubMed Web of Science ®Google Scholar
• Weisbart RH, Kacena A, Schuh A, Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-8
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988;109:789-95
   PubMed Web of Science ®Google Scholar
• Zsebo KM, Cohen AM, Murdock DC, et al. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 1986;172:175-84
   PubMed Web of Science ®Google Scholar
• Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-13
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454-61
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22
   PubMed Web of Science ®Google Scholar
• Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-72
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. The International Acute Myeloid Leukemia Study Group. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:4710-18
   PubMed Web of Science ®Google Scholar
• Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871-7
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995;86:444-50
   PubMed Web of Science ®Google Scholar
• Fenk R, Hieronimus N, Steidl U, et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006;34:1296-302
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261-6
   PubMed Web of Science ®Google Scholar
• Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8
   PubMed Web of Science ®Google Scholar
• Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000;96:80-5
   PubMed Web of Science ®Google Scholar
• Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496-502
   PubMed Web of Science ®Google Scholar
• Masood N, Shaikh AJ, Memon WA, Idress R. Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 2008;1:418
   PubMedGoogle Scholar
• Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185-92
   PubMed Web of Science ®Google Scholar
• Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol 2008;26:4355-6
   PubMed Web of Science ®Google Scholar
• Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001;27:689-92
   PubMed Web of Science ®Google Scholar
• Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006;135:642-50
   PubMed Web of Science ®Google Scholar
• Donadieu J, Leblanc T, Bader MB, et al. Experience of the French Severe Chronic Neutropenia Study Group. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Haematologica 2005;90:45-53
   PubMed Web of Science ®Google Scholar
• Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000;96:429-36
   PubMed Web of Science ®Google Scholar
• Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001;7:2085-90
   PubMed Web of Science ®Google Scholar
• Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Morishita M, Leonard RC. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther 2008;8:993-1001
   PubMed Web of Science ®Google Scholar
• Ballestrero A, Boy D, Gonella R, et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008;87:49-55
   PubMed Web of Science ®Google Scholar
• Holloway CJ. Applications of recombinant DNA technology in the production of glycosylated recombinant human granulocyte colony stimulating factor. Eur J Cancer 1994;30A(Suppl 3):S2-6
   PubMedGoogle Scholar
• Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994;30A(Suppl 3):S12-14
   PubMedGoogle Scholar
• Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996;16:1781-5
   PubMed Web of Science ®Google Scholar
• Mire-Sluis AR, Das RG, Thorpe R. The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. Participants of the Collaborative Study. J Immunol Methods 1995;179:117-26
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008;83:644-8
   PubMed Web of Science ®Google Scholar
• Sourgens H, Lefrere F. A systematic review of available clinical evidence - filgrastim compared with lenograstim. Int J Clin Pharmacol Ther 2011;49:510-18
   PubMed Web of Science ®Google Scholar
• Kuga T, Komatsu Y, Yamasaki M, et al. Mutagenesis of human granulocyte colony stimulating factor. Biochem Biophys Res Commun 1989;159:103-11
   PubMed Web of Science ®Google Scholar
• Okabe M, Asano M, Kuga T, et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood 1990;75:1788-93
   PubMed Web of Science ®Google Scholar
• Asano M, Gomi K, Okabe M. Characterization of the receptor for granulocyte colony-stimulating factor (G-CSF) on murine myeloblastic leukemia cell, NFS-60, using NTG, a mutant G-CSF, and analysis of the structure-activty relationship. Jpn Pharmacol Ther 1991;19:373-9
   Google Scholar
• Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993;82:1981-4
   PubMed Web of Science ®Google Scholar
• Russell NH, Hunter A, Rogers S, et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993;341:1482
   PubMed Web of Science ®Google Scholar
• Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000;25:85-9
   PubMed Web of Science ®Google Scholar
• Makinoda S, Hirosaki N, Waseda T, et al. Granulocyte colony-stimulating factor (G-CSF) in the mechanism of human ovulation and its clinical usefulness. Curr Med Chem 2008;15:604-13
   PubMed Web of Science ®Google Scholar
• Klocke R, Kuhlmann MT, Scobioala S, et al. Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Curr Med Chem 2008;15:968-77
   PubMed Web of Science ®Google Scholar
• Xiao BG, Lu CZ, Link H. Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection. J Cell Mol Med 2007;11:1272-90
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Dunn JA, et al. NEAT: national Epirubicin Adjuvant Trial–toxicity, delivered dose intensity and quality of life. Br J Cancer 2008;99:1226-31
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van HA, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277-83
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008;87:429-30
   PubMed Web of Science ®Google Scholar
• Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009;114:479-84
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009;CD007107
   Google Scholar
• Pabst T, Vellenga E, van PW, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012;119:5367-73
   PubMed Web of Science ®Google Scholar
• Bernasconi C, Alessandrino EP, Bernasconi P, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998;102:678-83
   PubMed Web of Science ®Google Scholar
• Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607-13
   PubMed Web of Science ®Google Scholar
• Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013;19:1104-10
   PubMed Web of Science ®Google Scholar
• Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142:505-12
   PubMed Web of Science ®Google Scholar
• Keiser P, Rademacher S, Smith J, Skiest D. G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection. Int J STD AIDS 1998;9:394-9
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-12
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011;2:859-66
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 2009;7:193-205
   PubMedGoogle Scholar
• Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 2009;95:219-26
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009;12:217-25
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25:401-11
   PubMed Web of Science ®Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-9
   PubMed Web of Science ®Google Scholar
• Perrier L, Lefranc A, Perol D, et al. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy 2013;11:129-38
   PubMedGoogle Scholar
• Bojke L, Sculpher M, Stephens R, et al. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial. Pharmacoeconomics 2006;24:443-52
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, Buijt I, van der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:1109-17
   PubMed Web of Science ®Google Scholar
• Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer 2013;21:841-6
   PubMed Web of Science ®Google Scholar
• Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics 2012;30:497-511
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-71
   PubMedGoogle Scholar
• Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 2011;103:979-82
   PubMed Web of Science ®Google Scholar
• Fishman ML, Kumar A, Davis S, et al. Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. J Oncol Pract 2012;8:e14s-7s
   PubMedGoogle Scholar
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-5
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 2012;18:171-9
   PubMedGoogle Scholar
• Abegg AL, Vickery LE, Bremer ME, et al. The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist. Leukemia 2002;16:316-26
   PubMed Web of Science ®Google Scholar
• Farese AM, Casey DB, Smith WG, et al. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells 2001;19:522-33
   PubMed Web of Science ®Google Scholar
• MacVittie TJ, Farese AM, Davis TA, et al. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates. Exp Hematol 1999;27:1557-68
   PubMed Web of Science ®Google Scholar
• MacVittie TJ, Farese AM, Smith WG, et al. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 2000;95:837-45
   PubMed Web of Science ®Google Scholar
• McWherter CA, Feng Y, Zurfluh LL, et al. Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin. Biochemistry 1999;38:4564-71
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Cantin J, Chang J, et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 2002;3:268-75
   PubMedGoogle Scholar
• Curtis BM, Williams DE, Broxmeyer HE, et al. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA 1991;88:5809-13
   PubMed Web of Science ®Google Scholar
• Taylor DS, Lee Y, Sieff CA, et al. Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Br J Haematol 1998;103:304-7
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Papadopoulos NE, Burgess MA, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 1994;12:715-24
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Broxmeyer HE, Andreeff M, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995;86:2098-105
   PubMed Web of Science ®Google Scholar
• Fleming WH, Mulcahy JM, McKearn JP, Streeter PR. Progenipoietin-1: a multifunctional agonist of the granulocyte colony-stimulating factor receptor and fetal liver tyrosine kinase-3 is a potent mobilizer of hematopoietic stem cells. Exp Hematol 2001;29:943-5
   PubMed Web of Science ®Google Scholar
• Ishioka GY, Fikes J, Qin M, et al. Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. Vaccine 2001;19:3710-19
   PubMed Web of Science ®Google Scholar
• Streeter PR, Minster NI, Kahn LE, et al. Progenipoietins: biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor. Exp Hematol 2001;29:41-50
   PubMed Web of Science ®Google Scholar
• Ramprasad MP, Amini A, Kararli T, Katre NV. The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int J Pharm 2003;261:93-103
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Rowe V, Filippich C, et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood 2003;101:2033-42
   PubMed Web of Science ®Google Scholar
• Morris ES, MacDonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 2005;115:3093-103
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Lee PP, Scotland R, et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003;9:1301-12
   Google Scholar
• Fuh G, Cunningham BC, Fukunaga R, et al. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256:1677-80
   PubMed Web of Science ®Google Scholar
• Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23
   PubMed Web of Science ®Google Scholar
• Youssoufian H, Longmore G, Neumann D, et al. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:2223-36
   PubMed Web of Science ®Google Scholar
• Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 1997;89:473-82
   PubMed Web of Science ®Google Scholar
• Liu Z, Stoll VS, Devries PJ, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007;110:2408-13
   PubMed Web of Science ®Google Scholar
• Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998;37:3699-710
   PubMed Web of Science ®Google Scholar
• Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-64
   PubMed Web of Science ®Google Scholar
• Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32
   PubMed Web of Science ®Google Scholar
• Conzelmann N, Schneider A. A screen for peptide agonists of the G-CSF receptor. BMC Res Notes 2011;4:194
   PubMedGoogle Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995;13:369-98
   PubMed Web of Science ®Google Scholar
• Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621-51
   PubMed Web of Science ®Google Scholar
• Shimoda K, Feng J, Murakami H, et al. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. Blood 1997;90:597-604
   PubMed Web of Science ®Google Scholar
• Tian SS, Lamb P, Seidel HM, et al. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 1994;84:1760-4
   PubMed Web of Science ®Google Scholar
• Tian SS, Lamb P, King AG, et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998;281:257-9
   PubMed Web of Science ®Google Scholar
• Hu ZT, Huang ZH, Cen XB, et al. F-627, a G-CSF dimer, stimulated a more rapid neutrophil recovery in cuclophosphamide-treated monkeys compared to monomer Rhg-CSFs. 116th edition. 2010
   Google Scholar
• Yan XQ, Hodsman PG, Huang ZH, et al. An open label, single ascending dose phase I study of F-627, a G-CSF dimer, in healthy male subjects. Blood 2010;116:4227
   Google Scholar
• Marschke K, Rungta D, Slavin DA, et al. Discovery of non-peptidyl small-molecule human G-CSF receptor agonists for the potential treatment of neutropenia. Blood 2011;118:3391
   Google Scholar
• Bar-Yehuda S, Madi L, Barak D, et al. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 2002;30:1390-8
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Barer F, et al. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 2001;269:230-6
   PubMed Web of Science ®Google Scholar
• Emanuel PD, Wang Z, Cai D, et al. TLK199 (Telintra TM), a novel glutathione analog inhibitor of GST P1-1, causes proliferation and maturation of bone marrow precursor cells and correlates with clinical improvement in Myelodysplastic Syndrome (MDS) patients in a phase 2a study. 104th edition. 2004. p. 652a
   Google Scholar
• Stofega MR, Cheng M, Ma H, et al. Telintra® (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production. Blood 2006;108:1161
   Google Scholar
• Lyons RM, Wilks ST, Young S, Brown GL. Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP-1-1) inhibitor. J Hematol Oncol 2011;4:43-7
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Smith SE, et al. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 2012;118:2138-47
   PubMed Web of Science ®Google Scholar